Key points from article :
Short safety trial on removing senescent cells from patients with lung fibrosis becomes successful.
There was marked improvement in physical function after nine doses over three weeks.
But lung function, clinical test outcomes, frailty levels and overall health did not change.
Used the senolytic dasatinib plus quercetin, an open-label drug, to clear the senescent cells.
This is only the first step of going into human trials.
A collaborative research published in EBioMedicine.
